Gene · 5898
RALA: RAS like proto-oncogene A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. RALA: RAS like proto-oncogene A. Genes, record 5898. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5898
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P11233 | Ras-related protein Ral-A | 206 | 16 | Ensembl, GeneID, HGNC |
Source UniProt
Patents43
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4801540 A1 | 2026-09-09 | 2 | P11233 | Espacenet |
| WO 2026063308 A | 2026-03-26 | 4 | P11233 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 69750 | P11233 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 14 | P11233 | Espacenet |
| WO 2025183123 A | 2025-09-04 | 10 | P11233 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 14 | P11233 | Espacenet |
| JP 2023531506 A | 2023-07-24 | 33 | P11233 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 96985 | P11233 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 199956 | P11233 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9331 | P11233 | Espacenet |
1 to 10 of 43
See all 43 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,792
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | RALA papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 16 | 2025 |
| P30CA006927 | Comprehensive Cancer Center Program at Fox Chase | 15 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 13 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 13 | 2025 |
| P40OD010440 | Caenorhabditis Genetics Center | 7 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 6 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 6 | 2025 |
| ZIABC010440 | Protein Structure, Stability, and Amyloid Formation | 6 | 2025 |
| ZIABC010441 | Biomolecular Recognition and Binding Mechanisms | 6 | 2025 |
| P30CA012197 | Cancer Center Support Grant | 5 | 2025 |
1 to 10 of 1,792Source NIH's project files
See all 1,792 nih grantsPapers2,381
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A RALGEF inhibitor suppresses lung cancer stem cell development and tumorigenesis. | J Biol Chem | 2026 | 42749263 | PubTator, text mining | PubMed |
| "RAL" the LDLR to lysosomes for degradation. | Life Metab | 2026 | 42701792 | PubTator, text mining | PubMed |
| Molecular mechanisms of chronic dietary cholesterol-driven remodeling of LDLR protein fate. | Yi Chuan | 2026 | 42608182 | PubTator, text mining | PubMed |
| Development and validation of QuadraSynth ML: a novel classifier for sepsis prediction. | Front Cell Infect Microbiol | 2026 | 42564150 | PubTator, text mining | PubMed |
| Single-Cell Transcriptomic Analysis Identifies an OLFM4-Associated Gastric Cancer Cell State with Palmitoylation-Related Signatures and Altered Metabolic Activities. | Biomolecules | 2026 | 42352346 | PubTator, text mining | PubMed |
| Dietary cholesterol activates a Ral-dependent pathway driving LDLR turnover. | Nature | 2026 | 42343138 | PubTator, text mining | PubMed |
| M-Sec promotes the production of infectious HIV-1 virus through the exocyst complex in macrophages. | PLoS Pathog | 2026 | 42224353 | PubTator, text mining | PubMed |
| Targeting the Ras-Ral Signaling Axis in Type 2 Diabetes Mellitus: A Dual-Modulation Approach to Correcting Insulin Resistance and β-Cell Dysfunction. | Pharmaceuticals (Basel) | 2026 | 42075902 | PubTator, text mining | PubMed |
| KCTD10 as a selective cancer dependency from transcription-replication conflicts (TRCs). | Ageing Cancer Res Treat | 2026 | 42037670 | PubTator, text mining | PubMed |
| Computational Approach Improves Diagnostic Performance Based on Tumor-Associated Autoantibodies in Esophageal Squamous Cell Carcinoma. | Comput Struct Biotechnol J | 2026 | 41971943 | PubTator, text mining | PubMed |
1 to 10 of 2,381
See all 2,381 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5898
GET https://conductscience.org/api/genes/v1/5898/patents?page=2